Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Approvals Near For Four New Drugs, One New Indication

Executive Summary

Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.

You may also be interested in...



US FDA Rejects Lilly’s Bid For Donanemab Accelerated Approval In Early Alzheimer’s

Lilly plans to seek traditional approval for its amyloid-clearing antibody after the Phase III TRAILBLAZER-ALZ 2 trial reads out in Q2, but it loses important ground in reimbursement negotiations.

J.P. Morgan Day Four: Talking With Execs About BD Plans

Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans. 

Pfizer Lays Out A Growth Plan To Offset $17bn In Coming Exclusivity Losses

Management presented a strategy for establishing new blockbuster brands in migraine, RSV, inflammatory bowel disease, cancer and diabetes/obesity during an investor day.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel